Fulgent Genetics’ Post

Join experts, Vladimir Bonevski and Kriti Jindal of IQVIA and Lien Lybaert of myNEO Therapeutics, on our latest webinar. Explore the evolving landscape of precision medicine and biomarker testing and its impact on oncology markets across different tumor types and geographies. Sign up: https://bit.ly/4cQjyjj #Oncology #PrecisionMedicine

Manta for oncology workflows 🧬 Running oncology workflows can be challenging. Working with tricky sample types and the constant struggle to meet those sky-high DNA/RNA quality standards. But, we’ve built Manta to tackle exactly these. ✅Flexible with sample load: Often oncology labs don’t get a heap of samples together. Manta can run just 1 or up to 32 samples in one go. ✅Enables various oncology applications: including diagnostics, BCR-ABL testing, and liquid biopsy research among others. ✅Optimal results: Manta delivers optimal results every time, no ifs, ands, or buts. If your lab works in the oncology sector and you’re looking to automate extraction workflows, let’s talk more: https://lnkd.in/guJ8VMND #oncology #molecularbiology #cancerdiagnostics #liquodbiopsy

How would we describe Molecular Partners in one word? Pioneers.    We are the inventors and developers of #DARPin therapeutics – an entirely new class of custom-built drugs – with the goal of transforming the lives of patients with serious diseases.     #RadioDARPins #cancerresearch #oncology #radiopharmaceuticals

Innovent is presenting clinical data on our first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein (IBI363) at the 2024 ESMO Virtual Plenary, June 13-14. Read below about this antibody's promising safety signals, its broad anti-tumor activity and its applicability across tumor types. #ESMOVirtualPlenary #oncology #InnoventBiologics https://lnkd.in/guaqFQmN

Discover the transformative potential of antibody-drug conjugates (ADCs) in targeted cancer therapy. Our latest presentation dives deep into the journey of ADC development, from Paul Ehrlich's early concept of "magic bullets" to their current status as a leading treatment modality. Learn about the intricate bioanalytical challenges, cutting-edge techniques, and regulatory milestones shaping the future of ADCs in oncology. #CancerResearch #ADCs #Bioanalysis #PrecisionMedicine #WuXiAppTec https://hubs.li/Q02zVC290

Our second-generation telomere targeting program is engaged in research and development for new drugs derived from THIO. Read further into the preclinical studies that have shown highly significant anti-cancer efficacy here: https://bit.ly/3Tk7f7M #Immunotherapy #Oncology

Our latest "Ask the Experts" features Dr. Robert Vries, CEO, diving deep into the exciting world of patient-derived organoids in cancer research! In this blog post, Dr. Vries explores: 💊The impact of the FDA Modernization Act 2.0 on organoid technology 🔬How organoids are revolutionizing oncology drug development 💊Our cutting-edge advancements in organoid services for drug discovery Discover how patient-derived organoids are paving the way for personalized cancer treatment. Read the full blog post here:https://bit.ly/4e445xA #cancerresearch #organoids #personalizedmedicine #drugdiscovery #innovation #tumororganoid #patientinthelab #oncology

🔬Our oncology webpages have recently gone through a revamp! Now you can easily navigate through InnoSer's oncology portfolio offering spanning from immuno-oncology in vitro assays to patient-derived xenograft (PDX) mouse models. 👉 View each model webpage, browse through example data and possible readout types now: https://lnkd.in/dtBrJD5E #OncologyCROServices #EuropeanOncologyCRO #ImmunoOncology #SyngeneicMouseModels #CellLineDerivedMouseModels #PatientDerivedOrganoids #HumanizedMouseModels 

Learn more about how to accelerate your #oncology #drugdiscovery, with Oncofactory's avian xenograft models for comprehensive early-phase assessment.

Our second session of day 2 at the Hail First Therapeutics Summit, titled "Oncology / Hematology Pharmacotherapy Update" starts with the moderator Dr.Yassmen Alsagheh #HTS24